---

Jean-Paul Clozel

Chief Executive Officer, Idorsia

Jean-Paul founded Actelion in 1997, together with his wife and work colleagues and friends, and has since built Actelion from a start-up to a multi-billion market capitalization company – acquired by Johnson & Johnson for €27.9 billion in 2017. As part of the transaction with J&J, Actelion spun out its drug discovery operations and early-stage clinical development assets into a newly created company, Idorsia, which Jean-Paul now heads up.

---

Part of the Power List 2018

The World’s Top 100 Medicine Makers

Bringing new drugs to patients is an incredibly difficult task that involves numerous indispensable actors – from pioneering entrepreneurs and CEOs, to industry experts, to dedicated researchers, to regulators who keep everyone on the right tracks.

Go to The Power List 2018